Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment [8]

Annals of the Rheumatic Diseases

Volumn 64, Issue 11, 2005, Pages 1665-1667

  Nikas, S N ^a   Voulgari, P V ^a   Takalou, I P ^a   Katsimbri, P ^a   Drosos, A A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INFLIXIMAB; METHOTREXATE;

ADULT; ALLERGIC REACTION; CLINICAL ARTICLE; FEMALE; HEALING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SACROILIITIS; SCORING SYSTEM; SORE THROAT; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27444445147     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.036178     Document Type: Letter

References (9)

1. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999;1:40-6.
2. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
3. Mease PJ. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 2004;16:360-70.
4. van de Kerkhof PC. The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion. Br J Dermatol 1997;137:661-2.
5. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35.
6. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: a randomized trial. Lancet 2001;357:1842-7.
7. Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
8. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurement of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
9. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumour necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.